Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gynecologic Cancer

 

Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator: Heidi J. Gray, MD;   Conditions: Cervical Cancer;    Status: Open;   Study ID: NCT00980954

Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

Investigator: Heidi J. Gray, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00565851

Elesclomol Sodium and Paclitaxel for Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (GOG 0260)
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Investigator: Heidi Gray, MD;   Conditions: Fallopian Cancer, Ovarian Cancer, Primary Peritoneal Cancer (PPC);    Status: Recruiting;   Study ID: NCT00888615

BIBF 1120 in Recurrent or Persistent Endometrial Cancer (GOG 229-K)
A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Endometrial Cancer;    Status: Closed;   Study ID: NCT01225887

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors (7750)
Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study

Investigator: Heidi J. Gray, MD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01641068

Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial--6973)
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)

Investigator: Nicole Urban, Sc.D., ScD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01121640

Rucaparib for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (CO-338-017)
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator: Elizabeth Swisher, MD;   Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01891344

Radiation Therapy Stage I or Stage II Cervical Cancer Post Surgery (GOG 0263)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Investigator: ;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01101451

MRI- and PET-Predictive-Assay for Cervical Cancer (8118)
MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Investigator: Nina Mayr, MD;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01992861

Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy for Gynecological Cancer (9191)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Investigator: Elizabeth Swisher, MD;   Conditions: Endometrial Cancer, Fallopian Cancer, Ovarian Cancer, Primary Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01968213

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Taking Care of Her (9306)
A Pilot Feasibility Study: Taking Care of Her

Investigator: Frances Lewis;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT02401321

Paclitaxel + Carboplatin w w/o Without Metformin Hydrochloride Endometrial Cancer (GOG 0286-B)
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Investigator: Heidi J. Gray, MD;   Conditions: Endometrial Cancer;    Status: Recruiting;   Study ID: NCT02065687

Trametinib w w/o GSK2141795 Endometrial Cancer (GOG 0299-O)
A Randomized Phase II Study With a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer

Investigator: Heidi J. Gray, MD;   Conditions: Endometrial Cancer;    Status: Pending;   Study ID: NCT01935973

Trametinib Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (GOG 0281)
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Investigator: Heidi J. Gray, MD;   Conditions: Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT02101788